Recenti progressi in medicina
-
In 2020 the percentage of patients with a diagnosis of cancer in people with more than 65 years will exceed 70% and 28% in ethnic minorities. The treatment of cancer in these populations is challenging for the oncologists due to socio-economic issues such as poverty, reduced access to the hospital care, level of education. The clinical pathway "diagnosis-treatment-cure", typical of the care of young patients has to be integrated in elderly patients with a more individualized treatment by means of comprehensive geriatric assessment (CGA). ⋯ Another important indicator is the disease specific survival (DSS). Concerning the design of clinical trials, a possible strategy is to enrol elderly patients without upper age limit and to plan stratification. An interesting trial design is the so called "extended trial" that allow to re-open the arm of a trial in which a too low number of older patients was enrolled.
-
The pharmaceutical and medical devices industry provides one of the main sources of scientific information for physicians. The impact of this kind of information on physicians' prescribing behavior has been extensively studied. Available evidence consistently shows that prescription habits are affected by industry-driven scientific research data. ⋯ Several American universities decided to prohibit any relationships between students and industry representatives. It would be desirable that such policies be adopted by other institutions. In addition, the practical guide published by the World Health Organization "Understanding and Responding to Pharmaceutical Promotion" should be better known and used.
-
The high state of anxiety about Ebola virus and its possible spread in the Western world has seemingly changed the route of the disease, for which effective vaccines and medicines do not exist. The rapid spread of the virus provides a paradigmatic narrative about the failure of today's governance for health, grounded on a series of global initiatives focussed on pathologies prioritized by the donors' community, at the detriment of health promotion and the strengthening of health systems in countries. ⋯ Today, the WHO is increasingly weak technically, politically and financially. While the virus remains out of control, the WHO's capacity to play a role in accompanying the development of the new essential vaccines and in brokering the conditions for accessibility and availability of the new medical tools remains to be questioned.
-
The management of chronic pain still represent a challenge for physicians. Opioids are the main stem in the treatment of chronic severe pain, not only for their potency, but as they act as central drugs. The main limit to their utilization in clinical practice is the prevalence of side effects, in particular in the gastrointestinal tract, whose constipation represents the most common. ⋯ In the case of TAP PR, instead, 0.31 QALYs were gained with additional savings due to the reduction of drug side effects, hospitalizations and emergency department access. Therefore, the use of TAP PR implies an average saving of € 31.6 per patient. These data are the results of a pharmacoeconomic model and require a further validation in clinical practice.
-
Adverse drug reactions affecting the skin have particular relevance as they may cause significant mortality and a possible modification of the benefit/risk profile of the concerned drug. The following entities are of special importance: Stevens Johnson syndrome (SJS), toxic epidermal necrolysis (TEN), acute generalized exanthematous pustulosis (AGEP) and drug rash with eosinophilia and systemic symptoms (DRESS). On the above mentioned reactions we focused our surveillance programme in the Lombardy region, the REACT-Lombardia project. ⋯ The risk for specific drug exposures was estimated by employing drug utilization data expressed as Defined Daily Doses (DDD). Mortality rate from SJS-TEN was 21%. Together with the registry, a "hub and spoke" clinical network for the management of severe cutaneous reactions was established with the Burn Unit of Niguarda Ca' Granda Hospital as the reference center for the most critical patients.